KH7 is a soluble adenylyl cyclase (sAC)-specific inhibitor, with IC₅₀s of 3-10 μM toward both recombinant purified human sAC_t protein and heterologously expressed sACt in cellular assays^[1]. KH7 is also a cAMP inhibitor^[2]. IC50 & Target: IC50: 3-10 μM (recombinant sAC_t)^[1]. In Vitro: KH7 (10 μM) blocks this capacitation-induced cAMP increase. At higher concentrations (50 μM), 5- to 10-fold above its IC50 but still selective for sAC relative to tmACs, KH7 resulted in a significant decrease in the basal cAMP accumulation in sperm regardless of the incubation medium^[1].
KH7 prevents the generation of CaSF^[2].
In the presence of KH7, the myocytes exerts a negative inotropic effect (NIE) of approximately 20%, suggesting that sAC is involved in the normal generation of basal cardiac contractility^[2].